



# How to Obtain Gamifant<sup>®</sup> (emapalumab-lzsg): An Overview of the Full-Service Patient Support Program and Distribution Model

## **Indication and Usage**

Gamifant<sup>®</sup> (emapalumab-lzsg) is an interferon gamma (IFN $\gamma$ )-blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

**Please see Important Safety Information on page 7 and accompanying full Prescribing Information.**



## Gamifant (emapalumab-lzsg) Patient Services (GPS) Offers One-on-One Assistance



GPS case managers are available to provide personal support for patients with primary hemophagocytic lymphohistiocytosis (HLH) and their caregivers



GPS case managers are trained to

- Help navigate treatment logistics with the site of care
- Provide insurance benefit and prior authorization (PA) research
- Assist with reimbursement, including patient financial assistance
- Assist with finding answers to product-related questions

Available to your patients and their caregivers 24 hours a day, 7 days a week



Contact **833-597-6530** to enroll your patients in GPS and get the support that they need

### Important Safety Information

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have positive purified protein derivative (PPD) test result or positive IFN $\gamma$  release assay.

During Gamifant treatment, patients should be monitored for TB, adenovirus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) every 2 weeks and as clinically indicated.

**Please see additional Important Safety Information on page 7 and accompanying full Prescribing Information.**



## Two Pathways to Seamless Delivery

### Direct Ordering

For direct product ordering through a specialty distributor (SD)

McKesson Plasma and Biologics

877-625-2566

McKesson Specialty Health

855-477-9800

An **SD** is a type of wholesale pharmaceutical distributor that is commonly used to supply drugs prescribed for rare and chronic diseases.

### Specialty Pharmacy

For prescriptions through a specialty pharmacy (SP)

Biologics, Inc.

800-850-4306

An **SP** is a licensed pharmacy designed to facilitate drug dispensing for products that require special handling and that may not be widely available at traditional retail pharmacies. **SP** ordering is for a specific (named) patient.

### Important Safety Information (continued)

Patients should be administered prophylaxis for herpes zoster, *Pneumocystis jirovecii*, and fungal infections prior to Gamifant administration.

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

**Please see additional Important Safety Information on page 7 and accompanying full Prescribing Information.**



## SD Direct Ordering for Gamifant (emapalumab-lzsg)



### Where to order Gamifant

#### McKesson Plasma and Biologics



Phone: 877-625-2566



Fax: 888-752-7626



Email: [mpborders@mckesson.com](mailto:mpborders@mckesson.com)



Online: [connect.mckesson.com](http://connect.mckesson.com)

#### McKesson Specialty Health



Phone: 855-477-9800



Online: [mckessonspecialtyhealth.com](http://mckessonspecialtyhealth.com)



### Shipping details

#### Gamifant is delivered within 24 hours of ordering

- McKesson validates shipping information
- Gamifant is shipped in a cold-chain pack to the administration site



For emergency same-day shipments, as well as emergency services for nights, weekends, and holidays, call McKesson Plasma and Biologics at **877-625-2566** or McKesson Specialty Health at **855-477-9800** and select **option 1**.



Call Gamifant Patient Services at **833-597-6530** with questions related to prior authorization or benefits investigation.

### Important Safety Information (continued)

#### Infusion-Related Reactions

Infusion-related reactions, including drug eruption, pyrexia, rash, erythema, and hyperhidrosis, were reported with Gamifant treatment in 27% of patients. In one-third of these patients, the infusion-related reaction occurred during the first infusion.

**Please see additional Important Safety Information on page 7 and accompanying full Prescribing Information.**

## SP Prescription Ordering for Gamifant (emapalumab-lzsg)



### How to process a prescription

- Provide Biologics with the prescription
- Contact SP with patient insurance information to verify benefits and understand delivery options
- Work with SP to complete a prior authorization, if required



### Three ways to send a prescription



Fax:  
800-823-4506



Phone:  
800-850-4306,  
option 2



E-scribe: Search your EMR using

- Pharmacy Name: Biologics
- Pharmacy Address:  
13000 Weston Parkway, Suite 105, Cary, NC 27513
- NCPDP: 3430369
- NPI: 1487640314



### Insurance verification

- Biologics verifies benefits and identifies patient's health plan requirements
- SP works with health plan and health care provider to obtain necessary information (prior authorization and additional documentation, if required)
- Biologics follows up with health plan to obtain insurance approval and may reach out to the health care provider if additional documentation is required



### Shipping details

#### Gamifant is delivered within 24 hours of ordering

- Biologics processes payments
- Biologics calls practice or facility to confirm shipment date and location with administration site (shipment will not go out until verbal confirmation is made)
- Gamifant is shipped in a cold-chain pack to the administration site

EMR=electronic medical record.

### Important Safety Information (continued)

#### Adverse Reactions

In the pivotal trial, the most commonly reported adverse reactions ( $\geq 10\%$ ) for Gamifant included infection (56%), hypertension (41%), infusion-related reactions (27%), pyrexia (24%), hypokalemia (15%), constipation (15%), rash (12%), abdominal pain (12%), CMV infection (12%), diarrhea (12%), lymphocytosis (12%), cough (12%), irritability (12%), tachycardia (12%), and tachypnea (12%).

**Please see additional Important Safety Information on page 7 and accompanying full Prescribing Information.**

## SP Prescription Ordering for Gamifant (emapalumab-lzsg) *(continued)*



### To ensure timely shipment, provide the following when sending a prescription

- The Gamifant prescription and explicit start date
- A written diagnosis and a diagnosis code for HLH (ICD-10-CM code D76.1)
- Complete and clear dosing instructions, including total dosage, quantity, and refills
- Patient information, including
  - Weight
  - Date of birth
  - Caregiver contact information
  - Copies of the front and back of all insurance cards, including prescription and medical, and demographic fact sheet
- Clinical information that supports the treatment decision, including pathology or laboratory reports, treatment history, and a description of the treatment plan

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

### **Important Safety Information** *(continued)*

#### **Adverse Reactions** *(continued)*

Additional selected adverse reactions (all grades) that were reported in less than 10% of patients treated with Gamifant included vomiting, acute kidney injury, asthenia, bradycardia, dyspnea, gastro-intestinal hemorrhage, epistaxis, and peripheral edema.

**Please see additional Important Safety Information on page 7 and accompanying full Prescribing Information.**



## Indication and Usage

Gamifant® (emapalumab-lzsg) is an interferon gamma (IFN $\gamma$ )-blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

## Important Safety Information

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have positive purified protein derivative (PPD) test result or positive IFN $\gamma$  release assay.

During Gamifant treatment, patients should be monitored for TB, adenovirus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) every 2 weeks and as clinically indicated.

Patients should be administered prophylaxis for herpes zoster, *Pneumocystis jirovecii*, and fungal infections prior to Gamifant administration.

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

## Infusion-Related Reactions

Infusion-related reactions, including drug eruption, pyrexia, rash, erythema, and hyperhidrosis, were reported with Gamifant treatment in 27% of patients. In one-third of these patients, the infusion-related reaction occurred during the first infusion.

## Adverse Reactions

In the pivotal trial, the most commonly reported adverse reactions ( $\geq 10\%$ ) for Gamifant included infection (56%), hypertension (41%), infusion-related reactions (27%), pyrexia (24%), hypokalemia (15%), constipation (15%), rash (12%), abdominal pain (12%), CMV infection (12%), diarrhea (12%), lymphocytosis (12%), cough (12%), irritability (12%), tachycardia (12%), and tachypnea (12%).

Additional selected adverse reactions (all grades) that were reported in less than 10% of patients treated with Gamifant included vomiting, acute kidney injury, asthenia, bradycardia, dyspnea, gastro-intestinal hemorrhage, epistaxis, and peripheral edema.

**Please see the full Prescribing Information for Gamifant.**



Gamifant is a registered trademark, licensed by Swedish Orphan Biovitrum AB (publ) and is marketed by Sobi, Inc.  
© 2018 Swedish Orphan Biovitrum. All rights reserved. PP-5088